Market Research Logo

Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2016

Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2016’, provides an overview of the Metastatic Adenocarcinoma of The Pancreas pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Adenocarcinoma of The Pancreas, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Adenocarcinoma of The Pancreas and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Metastatic Adenocarcinoma of The Pancreas
    • The report reviews pipeline therapeutics for Metastatic Adenocarcinoma of The Pancreas by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Metastatic Adenocarcinoma of The Pancreas therapeutics and enlists all their major and minor projects
    • The report assesses Metastatic Adenocarcinoma of The Pancreas therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Metastatic Adenocarcinoma of The Pancreas
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Metastatic Adenocarcinoma of The Pancreas
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Metastatic Adenocarcinoma of The Pancreas pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Metastatic Adenocarcinoma of The Pancreas Overview
    Therapeutics Development
    Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Overview
    Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis
    Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Development by Companies
    Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Investigation by Universities/Institutes
    Metastatic Adenocarcinoma of The Pancreas - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Metastatic Adenocarcinoma of The Pancreas - Products under Development by Companies
    Metastatic Adenocarcinoma of The Pancreas - Products under Investigation by Universities/Institutes
    Metastatic Adenocarcinoma of The Pancreas - Companies Involved in Therapeutics Development
    AbbVie Inc
    Aduro BioTech, Inc.
    Array BioPharma Inc.
    Axcentua Pharmaceuticals AB
    Berg LLC
    Boehringer Ingelheim GmbH
    Boston Biomedical, Inc.
    CTI BioPharma Corp.
    CytRx Corporation
    Daiichi Sankyo Company, Limited
    Eleison Pharmaceuticals LLC
    Gilead Sciences, Inc.
    GlaxoSmithKline Plc
    Incyte Corporation
    MabVax Therapeutics Holdings, Inc.
    Merrimack Pharmaceuticals, Inc.
    NewLink Genetics Corporation
    Novartis AG
    Oncolytics Biotech Inc.
    Pfizer Inc.
    Phoenix Biotechnology, Inc.
    Targovax ASA
    Metastatic Adenocarcinoma of The Pancreas - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    (curcumin + gemcitabine hydrochloride + paclitaxel) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    aldoxorubicin hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AXP-10711 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BI-853520 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    binimetinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy to Target GM-CSFR for Pancreatic Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ceritinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    glufosfamide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GS-5745 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GSK-2256098 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HuMab-5B1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ibrutinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    INCB-52793 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    indoximod - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    irinotecan hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MesoCART - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody Conjugate to Target Mesothelin for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    napabucasin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nimotuzumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    palbociclib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PBI-05204 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pelareorep - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PLX-7486 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PRI-724 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ribociclib succinate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SGT-53 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sonidegib phosphate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TG-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tosedostat - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ubidecarenone - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ulixertinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Metastatic Adenocarcinoma of The Pancreas - Dormant Projects
    Metastatic Adenocarcinoma of The Pancreas - Discontinued Products
    Metastatic Adenocarcinoma of The Pancreas - Product Development Milestones
    Featured News & Press Releases
    Aug 04, 2016: Merrimack Provides Update on ONIVYDE
    Jul 21, 2016: Baxalta receives CHMP positive opinion on Onivyde for the treatment of metastatic adenocarcinoma of the pancreas
    Jun 21, 2016: Merrimack to Present New Analyses of Phase 3 NAPOLI-1 Data at the ESMO 18th World Congress on Gastrointestinal Cancer
    May 18, 2016: AbbVie To Present Data on IMBRUVICA (ibrutinib) at ASCO 2016
    Apr 14, 2016: Targovax reports immune response with reduced number of TG01 vaccinations
    Jan 25, 2016: Boston Biomedical’s Investigational Cancer Stem Cell Pathway Inhibitor, Napabucasin (BBI608), Featured at the ASCO 2016 Gastrointestinal Cancers Symposium
    Jan 07, 2016: Baxalta Announces Priority Review Status Granted by Health Canada for irinotecan liposome injection (nal-IRI) for New Drug Submission
    Jun 25, 2015: MM-398 Receiving the Priority Review Designation by US FDA for New Drug Application and the Acceptance of Market Authorization Application by EMA in Post-Gemcitabine Metastatic Pancreatic Cancer
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas, H2 2016
    Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Development by Companies, H2 2016 (Contd..1)
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016 (Contd..1)
    Products under Investigation by Universities/Institutes, H2 2016
    Metastatic Adenocarcinoma of The Pancreas - Pipeline by AbbVie Inc, H2 2016
    Metastatic Adenocarcinoma of The Pancreas - Pipeline by Aduro BioTech, Inc., H2 2016
    Metastatic Adenocarcinoma of The Pancreas - Pipeline by Array BioPharma Inc., H2 2016
    Metastatic Adenocarcinoma of The Pancreas - Pipeline by Axcentua Pharmaceuticals AB, H2 2016
    Metastatic Adenocarcinoma of The Pancreas - Pipeline by Berg LLC, H2 2016
    Metastatic Adenocarcinoma of The Pancreas - Pipeline by Boehringer Ingelheim GmbH, H2 2016
    Metastatic Adenocarcinoma of The Pancreas - Pipeline by Boston Biomedical, Inc., H2 2016
    Metastatic Adenocarcinoma of The Pancreas - Pipeline by CTI BioPharma Corp., H2 2016
    Metastatic Adenocarcinoma of The Pancreas - Pipeline by CytRx Corporation, H2 2016
    Metastatic Adenocarcinoma of The Pancreas - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
    Metastatic Adenocarcinoma of The Pancreas - Pipeline by Eleison Pharmaceuticals LLC, H2 2016
    Metastatic Adenocarcinoma of The Pancreas - Pipeline by Gilead Sciences, Inc., H2 2016
    Metastatic Adenocarcinoma of The Pancreas - Pipeline by GlaxoSmithKline Plc, H2 2016
    Metastatic Adenocarcinoma of The Pancreas - Pipeline by Incyte Corporation, H2 2016
    Metastatic Adenocarcinoma of The Pancreas - Pipeline by MabVax Therapeutics Holdings, Inc., H2 2016
    Metastatic Adenocarcinoma of The Pancreas - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016
    Metastatic Adenocarcinoma of The Pancreas - Pipeline by NewLink Genetics Corporation, H2 2016
    Metastatic Adenocarcinoma of The Pancreas - Pipeline by Novartis AG, H2 2016
    Metastatic Adenocarcinoma of The Pancreas - Pipeline by Oncolytics Biotech Inc., H2 2016
    Metastatic Adenocarcinoma of The Pancreas - Pipeline by Pfizer Inc., H2 2016
    Metastatic Adenocarcinoma of The Pancreas - Pipeline by Phoenix Biotechnology, Inc., H2 2016
    Metastatic Adenocarcinoma of The Pancreas - Pipeline by Targovax ASA, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Metastatic Adenocarcinoma of The Pancreas - Dormant Projects, H2 2016
    Metastatic Adenocarcinoma of The Pancreas - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas, H2 2016
    Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report